Proving the Efficacy of Longevity Treatments: Epigenetic Clocks vs. VO₂ Max

A recent analysis by Healthi Life, a clinic specializing in longevity and regenerative medicine based in Bangkok, dives into how different biomarkers may influence the assessment of longevity treatments' effectiveness. The growing focus on longevity therapies has raised critical questions about how to accurately prove that these treatments are making a difference. Two prominent biological markers, epigenetic clocks and VO₂ max, present differing insights into the efficacy of these interventions.

Understanding the Metrics: Epigenetic Clocks

Epigenetic clocks are algorithms based on DNA methylation patterns that estimate biological age. These clocks have evolved over time, with second- and third-generation clocks, including GrimAge and PhenoAge, proving to be more relevant for assessing longevity than first-generation clocks, which are primarily chronologically oriented. The significance of epigenetic clocks lies in their ability to correlate biological aging with disease risk and mortality outcomes.

In the context of peptide-class therapies—substances aimed at promoting longevity—epigenetic clocks have demonstrated a remarkable capacity to identify statistically significant reductions in biological age under controlled conditions. For example, the TRIIM trial published in Aging Cell in 2019 found a notable decrease of 2.5 years in biological age after a growth hormone-based peptide regimen over 12 months. Following this, Corley et al. conducted a phase 2b trial indicating that semaglutide, a GLP-1 receptor agonist, led to a substantial 4.9-year reduction in PhenoAge. Such results underline the potential of these clocks as reliable indicators for tracking the effectiveness of longevity treatments.

VO₂ Max: The Longevity Predictor

Conversely, VO₂ max, the maximum capacity of an individual's body to transport and utilize oxygen during vigorous exercise, is traditionally regarded as a strong predictor of longevity and overall health. VO₂ max is particularly valued in clinical settings for its capacity to predict all-cause mortality better than many conventional risk factors. However, recent findings raise questions about its role in evaluating the outcomes of peptide therapy, particularly concerning weight loss interventions.

A review from the University of Virginia School of Medicine in 2025 noted no significant improvement in VO₂ max among participants receiving GLP-1 therapy, despite expectations that weight loss would typically enhance this measure. This paradox raises critical discussions about how one biometric may not capture the changes achieved by another treatment, highlighting the fact that VO₂ max and epigenetic clocks assess different biological dimensions.

The Importance of Measurement Frameworks

The contrasting findings between epigenetic clocks and VO₂ max suggest that the measurement frameworks clinicians choose greatly influence the perceived efficacy of treatments. A clinician may find statistically significant improvement in outcomes based on epigenetic clock adjustments while missing any changes in VO₂ max. This discrepancy indicates the necessity for healthcare providers to adopt a comprehensive approach when evaluating the effects of longevity therapies.

In light of this, it becomes evident that not all biomarkers are interchangeable or equally informative regarding biological aging. A sole focus on epigenetic clocks or VO₂ max can lead to misleading conclusions about a treatment's performance, underscoring the value of utilizing multiple biomarkers to obtain a fuller picture of a patient's healthspan.

Current Study Insights

The analysis from Healthi Life synthesized results from six peer-reviewed articles, revealing a significant evidence gap concerning widely prescribed wellness peptides like BPC-157, CJC-1295/Ipamorelin, and TB-500. A systematic review published in 2026 identified that none of these compounds have undergone long-term randomized controlled trials stipulating their efficacy in enhancing healthspan or longevity outcomes. This points to the urgency for more rigorous research and methodologically sound trials to solidify the scientific backing of commonly adopted therapies in the longevity space.

Conclusion: Navigating the Longevity Landscape

The findings from Healthi Life underscore the complexities and nuances inherent in measuring the efficacy of longevity treatments. With biomarkers such as epigenetic clocks and VO₂ max yielding different insights, clinicians must carefully consider which indicators they rely on to gauge treatment success. As research continues to unfold, the integration of comprehensive measurement strategies will be crucial in advancing the field of longevity and regenerative medicine, ultimately leading to better-targeted therapies and optimized patient outcomes.